WeTrials
Recruiting

A Phase 1 Dose Escalation Trial to Determine the Safety, Tolerance, Maximum Tolerated Dose, and Preliminary Antineoplastic Activity of IKS014, a HER2-Targeting Antibody Drug Conjugate (ADC), in Participants With Advanced HER2+ Solid Tumors

What is this study?

This study is testing an experimental medication called IKS014 for adults with advanced cancers, such as breast or stomach cancer. The goal is to find the safest and most effective dose of this new drug.

Who can participate?

You might be able to join if you have certain advanced solid tumors that test positive or low for the HER2 protein, and your general health meets specific blood test requirements. However, people with certain past lung conditions or current eye issues cannot participate.

What will happen?

Participants will receive the study medication while doctors closely monitor their safety, side effects, and how the drug affects their cancer. You will have regular health check-ups and blood tests throughout the process.

Where and when?

This study is currently recruiting participants and takes place at medical centers in Newport Beach, California; Boston, Massachusetts; and Nashville, Tennessee.

Key Points
  • 1Testing a new drug called IKS014 for advanced cancers
  • 2Currently recruiting patients at select US locations
  • 3Involves careful health monitoring and safety checks

No related links yet

Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.

Suggest a link
Conditions Studied
This study is investigating treatments for the following conditions
Breast CancerGastric CancerGastroesophageal-junction Cancer

This summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.